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Hereditary angioedema is an autosomal dominant disease characterized by recurrent angioedema attacks with
the involvement of multiple organs. The disease is unknown to many health professionals and is therefore
underdiagnosed. Patients who are not adequately diagnosed and treated have an estimated mortality rate ranging
from 25% to 40% due to asphyxiation by laryngeal angioedema. Intestinal angioedema is another important and
incapacitating presentation that may be the main or only manifestation during an attack. In this article, a group
of experts from the ‘‘Associac¸a˜o Brasileira de Alergia e Imunologia (ASBAI)’’ and the ‘‘Grupo de Estudos Brasileiro
em Angioedema Heredita´rio (GEBRAEH)’’ has updated the Brazilian guidelines for the diagnosis and treatment of
hereditary angioedema.
KEYWORDS: Hereditary Angioedema; Angioedema; C1 Inhibitor Deficiency; Coagulation Factor XII Mutations;
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’ WHY STUDY HEREDITARY ANGIOEDEMA?
Since the first Brazilian Hereditary Angioedema Guide-
lines were published in 2011, the body of knowledge regard-
ing hereditary angioedema (HAE) has increased, and its
management has improved (1-6). More patients have been
diagnosed with HAE, and new treatments for the disease
have become available in our country. In this article, a group
of experts in HAE from the Brazilian Association of Allergy
and Immunology (Associac¸ão Brasileira de Alergia e
Imunologia - ASBAI) and the Hereditary Angioedema
Brazilian Study Group (Grupo de Estudos Brasileiro em
Angioedema Hereditário - GEBRAEH) have updated the
guidelines for the diagnosis and therapy of hereditary
angioedema.
Prof. William Osler, who established the hereditary nature
of HAE, stated that ‘‘Medicine is both a science and an art’’.
Developing and applying evidence-based guidelines is funda-
mental for the practice of medicine as a science; however,
assisting individual patients with their biopsychosocial features
in a personalized manner is practicing medicine as an art.
HAE remains unknown to and underdiagnosed by many
health care providers. The long periods from the onset of
symptoms to the diagnosis of the disease and from diagnosis
to access to therapy increase HAE-related morbidity and
mortality, thus affecting the quality of life (QoL) of patients
and their families (1,2,5-9). HAE patients visit an average ofDOI: 10.6061/clinics/2018/e310
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4.4 physicians before receiving a correct diagnosis, and
65% of these patients are misdiagnosed (10,11). Although
HAE accounts for a minority of cases of angioedema, and the
initial estimate of its prevalence was 1:50,000 (ranging from
1:10,000 to 1:150,000), new subsets of patients with the disease
have been described; thus, the disease is more common than
previously thought (6,12-15). Physicians and other health
professionals should be aware of the clinical presentation of
HAE and of screening laboratory tests whose results may be
suggestive of its diagnosis. In addition, allergy and immu-
nology specialists must be updated with information on the
diagnosis and management of patients with HAE.
The two most severe clinical manifestations of HAE are
related to the upper airways and intestinal angioedema. Patients
who are not properly treated have estimated mortality rates of
25% to 40% due to asphyxiation by laryngeal angioedema
(3,5,12,16). In the United States, HAE accounts for 15,000-30,000
emergency room visits per year. These visits often lead to
hospitalization and admission to intensive care units (17,18).
Incapacitating intestinal angioedema is another major manifes-
tation of HAE, and the intestine can be the main or only organ
system involved in an attack. Such patients are often mis-
diagnosed as having an acute surgical abdomen and undergo
unnecessary surgeries (12,19,20). It is estimated that patients
with HAE experience some degree of disability for 20-100 days
per year (4,9).
’ WHAT IS HEREDITARY ANGIOEDEMA?
Angioedema is a localized, self-limiting, asymmetric and
disfiguring non-inflammatory edema of the deep dermis or
subcutaneous or submucosal tissues that occurs as a result
of vasodilation and increased vascular permeability. HAE
comprises a group of diseases characterized by recurrent
angioedema caused by excess bradykinin production, with
an autosomal dominant inheritance pattern.
’ WHAT ARE THE TYPES OF HEREDITARY
ANGIOEDEMA?
In an attempt to standardize nomenclature, an inter-
national panel of HAE experts issued a consensus statement
in which they proposed a classification for ‘‘Angioedema
without wheals’’ based mainly on the presence or absence of
C1-INH deficiency (4). The following three forms of HAE
have been defined:
1) HAE with quantitative C1-INH deficiency
(previously designated C1-INH-HAE Type-I)
HAE characterized by a quantitative decrease in C1-INH
expression to levels below 50% of the normal value and,
consequently, a decrease in functional protein activity. This
phenotype is the most prevalent form of HAE (80-85% of
cases of the disease are caused by C1-INH deficiency) (21).
2) HAE with C1-INH dysfunction (previously
designated C1-INH-HAE Type-II)
HAE in which C1-INH levels are normal or elevated, but
the function of the protein is impaired (22).
3) HAE with normal C1-INH (previously designated
HAE Type III)
This form of HAE, which was identified more recently
than the other forms of the disease, affects mainly women
but has also been identified in men. This form is character-
ized by clinical symptoms similar to those of HAE with
C1-INH deficiency, along with heritability and normal
C1-INH levels and function (15,23). HAE with normal C1-INH
has been associated with increased serum estrogen levels
(pregnancy and exogenous administration) and mutations in
the gene encoding FXII in a subset of patients (FXII-HAE).
However, in a significant percentage of cases, the genetic
defect remains unknown. Therefore, the following two
subtypes have been recognized: HAE with normal C1-INH
and FXII mutation (FXII-HAE) and HAE with normal
C1-INH and unknown genetic defect (U-HAE) (1,2,5-9,24).
It has been recommended that clinicians no longer use the
term HAE type III because it is not associated with C1-INH
deficiency.
’ WHAT IS THE CAUSE OF HEREDITARY
ANGIOEDEMA?
Quincke first described HAE as a clinical entity in 1882
(25-27), and Osler established its hereditary nature in 1888
(28-32). The first biochemical change associated with the
disease, C1 inhibitor (C1-INH) deficiency, was not identified
until 75 years later. Patients with HAE due to C1-INH defi-
ciency present with a quantitative or qualitative defect of
the protein, a serine protease inhibitor from the SERPIN
superfamily (33-35). The protein inhibits the first components
of the complement system-classical pathway, C1r and C1s
esterases, which bind to and activate C1q (36). In the absence
of such inhibition, the complement system becomes exces-
sively activated. C1-INH has also been recognized as an
inhibitor of several proteases, including plasma kallikrein,
coagulation factors XII (FXII) and XI, plasmin and MASP-1
and MASP 2, which are components of the complement
system-lectin pathway. Therefore, C1-INH inhibits the com-
plement system and participates in regulating the contact,
coagulation and fibrinolysis systems (37-39).
Episodes of angioedema were initially attributed to factors
formed during complement system activation, including
a C2 fragment (C2 kinin) associated with vasodilation and
increased permeability. Subsequent studies have revealed that
C1-INH deficiency results in over-activation of the contact
system (kallikrein-kinin system) and increased bradykinin
production (Figure 1). Bradykinin binds to its B2 receptor,
which is constitutively expressed on endothelial cells, and
decreases endothelial junctions, thereby increasing vascular
permeability and inducing angioedema (40,41). Bradykinin
also stimulates nitric oxide production, leading to vaso-
dilation induced by contraction of the cytoskeleton (42).
Evidence indicates that bradykinin is the main HAE
mediator (43,44).
In 1999, Nussberger et al. assessed plasma samples from
patients with HAE and observed that bradykinin levels
were higher in blood drawn from edematous sites than in
blood drawn from other sites that were not affected by the
disease (45). Another study showed that vascular perme-
ability was lower in knockout mice with concomitant C1-INH
and bradykinin receptor B2 (BDKRB2) deficiencies than in
mice with only C1-INH deficiency, demonstrating that the
bradykinin/BDKRB2 pathway plays an important role in
angioedema (46). The investigation and development of
new treatments, such as bradykinin receptor antagonist and
kallikrein inhibitors, has reinforced the role of bradykinin as the
main mediator of HAE (47,48).
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In conclusion, HAE with C1-INH deficiency occurs due to
decreased levels of the protein or as a consequence of the
production of a dysfunctional protein. Among patients with
HAE, the levels of functional C1-INH typically range from
5% to 30% of the normal value. One would expect the func-
tional level of the protein to reside at approximately 50% of
the normal value because almost all patients are hetero-
zygous for the mutation and thus bear a functioning allele
of the C1-INH gene (4,12). The reasons for the lower-than-
expected functional activity of C1-INH remain unclear. The
above findings suggest that additional mechanisms may
underlie HAE development.
In 2000, Bork et al. identified a new subset of patients with
HAE with normal C1-INH levels (15). Mutations of the gene
encoding coagulation factor XII (FXII), which segregated
within the families of patients with HAE with normal
C1-INH levels, were subsequently described. This HAE type
was designated FXII-HAE (49). FXII plays a central role in
the early stages of contact system activation by increasing
bradykinin synthesis (50). Initial observations suggested that
mutations in FXII lead to gain-of-function changes and
subsequent increases in bradykinin production; however,
subsequent studies have failed to confirm these earlier find-
ings, and the functional role of the observed mutations
remains unclear (51,52). By generating recombinant natural
and mutated variants of FXII, studies have recently shown
that FXII-HAE mutations introduce new sites that are sensi-
tive to enzymatic cleavage by plasmin, thus rendering FXII
mutants abnormally sensitive to plasmin. The FXII mutants
rapidly activate after cleavage by plasmin and escape from
inhibition through C1-INH, leading to excessive bradykinin
production. Interestingly, the authors provided evidence that
lysine analogs, including tranexamic acid and epsilon amino-
caproic acid, may attenuate these changes. This finding
explains the therapeutic value of these agents in patients
with FXII-HAE (53). However, not all patients with HAE with
normal C1-INH levels bear a mutation in FXII and, thus, have
HAE of unknown cause (U-HAE) (24). As is the case in HAE
with C1-INH deficiency, HAE with normal C1-INH levels
appears to be mediated by bradykinin.
Figure 1 - Kallikrein-kinin system.
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Patients with HAE do not present urticaria, experience
worsening symptoms with angiotensin-converting enzyme
inhibitors (ACEi) and estrogen treatments, fail to respond
to antihistamines and corticosteroids and improve with the
use of the bradykinin receptor B2 blocker (4,23). Affected
patients with HAE, especially those with normal C1-INH
levels, show worsening symptoms with exogenous estrogen
intake, such as that which occurs during contraception or
hormone replacement therapy (23,54). The mechanisms
underlying this deterioration are only partially understood.
The promoter region of the FXII gene contains an estrogen
responsive element, and increases in FXII mRNA transcrip-
tion in response to estrogen have been demonstrated (55).
It is likely that estrogen also contributes to the regulation of
B2 bradykinin receptor expression, modulates the kallikrein-
kinin cascade and reduces C1-INH levels (56,57).
’ WHAT ARE THE TYPICAL CLINICAL
MANIFESTATIONS OF HEREDITARY
ANGIOEDEMA?
The clinical history is an important component of the diagnosis
of HAE, and it has been well characterized in the cohorts
studied by Profs. Agostoni, Cicardi and Bork (2,3,5,11). Patients
with HAE suffer from recurrent attacks of edema involving
the skin and submucosa of several organs. HAE is not
associated with urticaria and is nonpruritic, but patients
sometimes describe experiencing a burning sensation in
edematous regions. The sites most commonly affected are the
face, extremities, genitalia, oropharynx, larynx and digestive
system. However, rare clinical manifestations of the disease,
such as intense headaches caused by brain edema, urinary
retention and acute pancreatitis, may also occur (58).
The frequency and severity of the above clinical manifesta-
tions vary among individuals. It has been reported that
5% of patients with HAE are asymptomatic and that
25% develop sporadic symptoms (5,6,13,15). A retrospective
study analyzing 131,110 attacks in 221 patients with HAE
reported that laryngeal edema occurred in less than 1% of
attacks, although over 50% of patients enrolled in the study had
previously experienced this particular manifestation at least
once (5).
HAE attacks typically last 48-72 hrs if left untreated and do
not improve with administration of antihistamines, cortico-
steroids or epinephrine. Although many attacks occur spon-
taneously, several factors that trigger them have been identified,
including minor trauma, stress, infection, menstruation, preg-
nancy, alcohol consumption, extreme temperature changes,
exercise, ACEi use and estrogen use (contraceptives and
hormone replacement therapy) (2,3,5,11).
In some patients, erythema serpiginous can occur as a
prodromal manifestation preceding an HAE attack, but
the concomitant presence of pruritic urticaria favors the
diagnosis of histaminergic angioedema, making the diag-
nosis of HAE unlikely (5). Nevertheless, some cases of HAE
accompanied by urticaria have been reported. In addition to
the above phenomenon, irritability, weakness, nausea and
‘‘flu sensations’’ have also been reported as prodromal
manifestations of the disease.
During adolescence, patients may experience substantial
increases in disease activity. In particular, girls may expe-
rience increases in disease activity due to menstruation or the
use of contraceptives containing estrogen. A family history of
angioedema is suggestive of a diagnosis of HAE; however,
this history may be absent in up to one-fourth of affected
patients.
Although the clinical manifestations of HAE with normal
C1-INH are similar to those of other types of HAE, there are
some differences between them. Symptom onset generally
occurs later in this type of HAE, and the course of the disease
tends to be more benign than that of others. Moreover, tongue
involvement is common. Bruising is occasionally seen at sites
affected by angioedema. However, the most striking char-
acteristic of HAE with normal C1-INH is its association with
female gender and estrogen intake (24). We have generated
a list of warning signs of the disease and have also devised
an acronym to increase awareness of HAE. These items are
presented in Figure 2.
’ HOW CAN LABORATORY TESTS CONFIRM THE
DIAGNOSIS OF HEREDITARY ANGIOEDEMA?
Individuals clinically suspected of having HAE and
those with a family history of HAE should be investigated
(Figure 3). Serum C4 levels can be used as a screening test
because quantitative or qualitative C1-INH deficiency leads
to permanent complement system activation, which is accom-
panied by C4 consumption, even when patients are not
experiencing an angioedema attack. C4 levels normalize during
the inter-crisis period in only 2-5% of patients with HAE
(3,5,10,16). However, determining C3 levels is unnecessary,
as C3 levels are normal in patients with HAE because C3
has greater turnover than C4, and C1-INH does not directly
regulate its activation. Additionally, C3 levels and activity are
regulated by other factors, such as factors H and I from the
alternative complement pathway.
Figure 2 - A: Warning Signs. B: HAAAAE for Heredity, recurrent Angioedema, recurrent Abdominal pain, Absence of urticaria, Absence
of response to antihistamines and association with Estrogen.
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In addition to performing measurements of serum C4
levels, quantitative and functional evaluations of C1-INH
should be performed. All health professionals and family
members involved in providing care for patients with HAE
must ensure that such tests are available. Although quanti-
tative determination of C1-INH levels is relatively easy,
evaluations of functional C1-INH activity (qualitative tests)
must be performed at referral laboratories (12,14,18). Ideally,
these tests should be performed immediately after sample
collection to avoid degradation. However, as this is not
feasible in most cases, reliable test results can be achieved
when samples are properly stored and the tests performed
with adequate methodology. When using the chromogenic
functional assay, it is critical that samples are kept at -20oC in
all steps of the process, including storage and transportation,
for accurate results (59,60). It is mandatory to avoid freezing
and thawing the same sample more than once for functional
C1-INH evaluation. A functional activity test is usually per-
formed only when the quantitative determination of C1-INH
is normal (Figure 3). However, some studies suggest that
functional activity could be a suitable screening test in addi-
tion to C4 level measurement, considering that functional
activity would be decreased in all patients with HAE due to
C1-INH deficiency (types I and II) (60).
If the clinical suspicion of HAE due to C1-INH deficiency
remains in the presence of normal C4 levels, the test should
be repeated during an episode of angioedema whenever
possible, as C4 levels are occasionally (2-5%) normal between
attacks (61). If the test result is again normal, and quantitative
and qualitative levels of C1-INH are normal, a diagnosis of
HAE with normal C1-INH is suggested, a condition in which
all of these biochemical parameters are normal (17).
Analysis of SERPING1, the gene encoding C1-INH, may
be performed in cases of undefined diagnoses or for research
purposes. Mutations can be identified in one of the eight
exons or exons/introns adjacent regions of the gene, which
affect the production of the protein and/or its function. Not
all mutations detected by routine genetic testing are disease-
causing, and genetic testing of other affected and disease-free
family members is sometimes needed. Genotyping may
be recommended whenever a discrepancy exists between a
patient’s clinical history and laboratory test results and in new-
borns or infants or specific situations, such as when patients
with late-onset disease or no family history of disease present
with clinical symptoms suggestive of HAE (62,63).
Factor XII gene mutations have been identified in a sub-
set of patients with HAE with normal C1-INH. Initially,
genetic sequencing detected two different missense muta-
tions in exon 9: one encodes a threonine-to-lysine substitution
(p.Thr328Lys), and the other encodes a threonine-to-arginine
substitution (p.Thr328Arg) (49). Novel mutations have sub-
sequently been published: a mutation featuring a deletion of
72 base pairs (c.971_1018+24del72), which was reported in a
family originating from Turkey; and a mutation featuring a
duplication of 18 base pairs (c.892_909dup), which has been
described in patients from Hungary (64,65).
In acquired angioedema with C1-INH deficiency (C1-INH
AAE), a condition associated with lymphoproliferative or
autoimmune diseases, paraproteins induce the activation and
consumption of complement components. Therefore, deter-
mining C3 and C1q levels, the latter of which are reduced in
75% of patients, may aid clinicians in differentiating between
HAE and AAE. In addition to C1q consumption, anti-C1-
INH antibodies may be observed in AAE associated with
autoimmune disease (66).
’ WHATARE THE DIAGNOSTIC CRITERIA FOR HAE?
Criteria with which the diagnosis of HAE with C1-INH
deficiency can be standardized have been proposed (Table 1).
According to those criteria, the diagnosis of HAE is con-
firmed when patients meet one primary clinical and one
biochemical disease criterion (12,19,20). It should be high-
lighted that the criteria are not absolute and that clinical
history takes precedence over laboratory findings, particularly
in localities in which laboratory tests are not available.
In selected cases, a therapeutic test can aid in establishing the
diagnosis of HAE.
Figure 3 - Algorithm of HAE diagnosis.
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The diagnosis of HAE with normal C1-INH is considered
in patients with recurrent angioedema not associated with
urticaria and with normal C1-INH activity and plasma
protein levels. A history of one or more family members also
being affected by the disease, along with a history of the
disease occurring predominantly in female family members,
makes the diagnosis more likely. At this time, the only
confirmatory test for HAE with normal C1-INH is the study
of the F12 gene to identify one of the mutations that has been
described (FXII-HAE) (9,17).
’ WHAT IS NOT HEREDITARY ANGIOEDEMA?
Two major pathophysiological mechanisms underlying the
development of angioedema have been described. Angio-
edema can be induced by the activation of mast cells and/or
basophils, resulting in the release of histamine and other
mediators (histaminergic angioedema), and by an excess
of bradykinin (bradykinin-mediated or non-histaminergic
angioedema), as seen in HAE, acquired angioedema with
C1-INH deficiency (AAE) and angioedema induced by ACEi
and other drugs involved in bradykinin metabolism (4,29).
A scheme in which angioedema is classified according to
endotype has recently been proposed andmay provide clinicians
with insights into the etiology of the disease and/or the
pathophysiological mechanism underlying the development of
the different types of this clinical entity (Figure 4) (25,27,33-35).
The differential diagnosis for HAE encompasses other
types of angioedema, mainly those with chronic or recurrent
presentations. The most frequent type of recurrent angio-
edema is the histaminergic type, which is usually associated
with urticaria. This type can be induced or exacerbated by
the use of non-steroidal anti-inflammatory drugs (NSAIDs)
(28,30-32,36). The presence of urticaria, the improvement
of the disease with the administration of antihistamines,
and the triggering of symptoms by NSAIDs intake make the
Table 1 - Diagnostic Criteria for Hereditary Angioedema with
C1-INH Deficiency (12,26).
I – Primary clinical criteria
a) Non-inflammatory subcutaneous angioedema lasting longer than
12 hrs
b) Abdominal pain with no specific etiology lasting longer than 6 hrs
c) Laryngeal edema
II – Secondary clinical criteria
a) Family history of hereditary angioedema
III – Biochemical criteria
a) Quantitative C1-INH deficiency (o50%, in two distinct samples)
b) Functional C1-INH deficiency (o50%, in two distinct samples)
c) Mutation in the gene encoding C1-INH (SERPING1)
Figure 4 - Classification of Angioedema by Endotypes (25,27).
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diagnosis of HAE less likely in a patient with angioedema.
However, chronic histaminergic angioedema can present
without urticaria, and NSAIDs are one of the major causes
of angioedema without urticaria (25). In contrast, it is not
necessary to avoid prescribing NSAIDs for patients with
HAE, as the pathophysiological mechanisms underlying the
development of angioedema are different.
The current guidelines for treating chronic spontaneous
urticaria/angioedema highlight the fact that some patients
will not respond to conventional doses of antihistamines and
may need their dose increased to levels as high as four times
the recommended daily doses to control their symptoms.
Therefore, a trial with an antihistaminic agent administered
at four times the recommended dose is warranted. This trial
must last for a period of time sufficient to determine whether
the angioedema has been controlled to confirm or rule out its
histaminergic nature. The safety of up-dosing antihistamines,
including cetirizine, levocetirizine, desloratadine, fexofenadine
and rupatadine, has been documented in previous studies (67).
It is very important to ask patients about the use of ACEi
when attempting to diagnose acquired forms of bradykinin-
mediated angioedema. As ACE is the major enzyme involved
in bradykinin degradation, its inhibition leads to increased
serum concentrations of this mediator and may cause
angioedema. ACEi should be withdrawn in all patients with
recurrent angioedema, even if the angioedema developed
several years after treatment onset. Up to 0.7% of individuals
who take ACEi present with recurrent angioedema, and the
risk of the disease is increased among African-descendants,
smokers, elderly patients and females (68,69). ACEi-induced
angioedema more frequently involves the face, tongue, neck
and larynx than other sites; however, sporadic cases of
abdominal attacks have been reported. The mean time for the
onset of angioedema symptoms is 1.8 years after treatment
initiation; however, symptoms occur in the first month post-
treatment initiation in 25% of cases and may occur up to
10 years after ACEi treatment initiation (70). Although symp-
toms of angioedema induced by ACEi may resemble those
of HAE, affected patients will have normal C4 and C1q
levels and normal C1-INH levels and function. More rarely,
angiotensin II receptor antagonists (ARBs) and gliptins,
which are oral hypoglycemic agents that inhibit dipeptidyl
peptidase IV, another enzyme involved in bradykinin cata-
bolism, may also induce angioedema (71).
AAE is another form of angioedema characterized by
C1-INH deficiency (C1-INH AAE); however, this disease
is not inherited. In C1-INH AAE, the onset of symptoms
occurs later, there is no family history of angioedema and
the disease is caused by the consumption of C1-INH or the
production of C1-INH-neutralizing autoantibodies, which
are associated with lymphoproliferative disorders or auto-
immune diseases, respectively (12,72,73). As a consequence,
C1-INH activity is low, the complement system is activated
and C1q levels are usually decreased, a particular feature
that can aid disease diagnosis (74,75). Moreover, C1-INH
function decreases to levels less than 50% of normal, and
C1-INH antigen levels are generally decreased, although the
presence of cleaved C1-INH may result in apparently normal
C1-INH antigen levels in approximately 20% of patients
(74,76). C1-INH AAE with autoantibodies and C1-INH AAE
with lymphoproliferative diseases largely overlaps and
should be considered the same disease (4).
Idiopathic non-histaminergic angioedema is characterized
as non-hereditary and is diagnosed in cases in which all
known causes of angioedema have been excluded. Its symp-
toms persist despite treatment with high doses of antihista-
mines, doses that are typically as high as 4 times the standard
doses of second-generation, non-sedating antihistamines. Some
evidence exists indicating that bradykinin may be the mediator
involved in the development of idiopathic non-histaminergic
angioedema; however, this evidence is not definitive, as other
vasoactive mediators, including cysteinyl-leukotrienes, prosta-
glandins and platelet-activator factor, may play a role in the
development of the disease in some patients. Treating patients
with idiopathic non-histaminergic angioedema is often a chal-
lenge in clinical practice, and no definitive recommendations
for the treatment of such patients are reliable. The capacity of
tranexamic acid and icatibant to alleviate symptoms has been
reported in individual cases. Cyclosporine and omalizumab
have also been used to treat affected patients, indicating that
this group of patients is heterogeneous. We speculate that this
classification may include patients with HAE with normal
C1-INH levels and without a family history of the disease and
patients with chronic spontaneous urticaria/angioedema resis-
tant to antihistamines, given that up to 10% of these patients
present with recurrent angioedema without urticaria (4,27,67).
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